HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lendvai, N. Articles by Casadevall, A. Search for Related Content PubMed PubMed Citation Articles by Lendvai, N. Articles by Casadevall, A. Pubmed/NCBI databases Compound via MeSH Substance via MeSH

Mechanism for the Isotype Dependence of Antibody-Mediated Toxicity in Cryptococcus neoformans-Infected Mice¹

Nikoletta Lendvai^*, Xiao-Wu Qu, Wei Hsueh and Arturo Casadevall^2,*

^* Departments of Microbiology and Immunology and Medicine, Albert Einstein College of Medicine, Bronx, NY 10461; and Departments of Pathology and Pediatrics, Children’s Memorial Medical Center, Northwestern University Medical School, Chicago, IL 60614

Ab-based therapies have undergone a renaissance in recent years, but infusion-related reactions are a significant clinical problem. Administration of certain mAbs to Swiss Webster mice infected with Cryptococcus neoformans can result in acute lethal toxicity (ALT) characterized by cardiovascular collapse. The ability of a mAb to produce ALT is isotype dependent and occurs with IgG1 but not IgG3. To investigate this phenomenon, we measured spleen and liver cytokine responses and platelet-activating factor (PAF) content in mice given C. neoformans glucuronoxylomannan (GXM) followed by specific Ab of IgG1 or IgG3 isotype. We found no evidence to suggest that the differences in IgG1 and IgG3 toxicity were due to differences in chemokine or cytokine response. In contrast, liver and spleen tissue PAF content was significantly greater in mice IgG1. Furthermore, our results show differences in the response to IgG1- and IgG3-GXM complexes regarding: 1) macrophage-inflammatory protein-1 and monocyte chemoattractant protein-1 regulation, 2) splenic and hepatic PAF content, and 3) hepatic PAF content in infected mice. IgG1-associated ALT appears to be the result of greater production of PAF in response to IgG1-GXM complex formation. The results are consistent with the view that IgG1 and IgG3 interact with different Fc receptors. Our findings strongly suggest that the mechanism for Ab-mediated ALT is different from the cytokine release syndrome described after administration of other therapeutic mAbs.

This article has been cited by other articles:

				A. Rachini, D. Pietrella, P. Lupo, A. Torosantucci, P. Chiani, C. Bromuro, C. Proietti, F. Bistoni, A. Cassone, and A. Vecchiarelli An Anti-{beta}-Glucan Monoclonal Antibody Inhibits Growth and Capsule Formation of Cryptococcus neoformans In Vitro and Exerts Therapeutic, Anticryptococcal Activity In Vivo Infect. Immun., November 1, 2007; 75(11): 5085 - 5094. [Abstract] [Full Text] [PDF]

				D. O. Beenhouwer, E. M. Yoo, C.-W. Lai, M. A. Rocha, and S. L. Morrison Human Immunoglobulin G2 (IgG2) and IgG4, but Not IgG1 or IgG3, Protect Mice against Cryptococcus neoformans Infection Infect. Immun., March 1, 2007; 75(3): 1424 - 1435. [Abstract] [Full Text] [PDF]

				F. Woelbing, S. L. Kostka, K. Moelle, Y. Belkaid, C. Sunderkoetter, S. Verbeek, A. Waisman, A. P. Nigg, J. Knop, M. C. Udey, et al. Uptake of Leishmania major by dendritic cells is mediated by Fc{gamma} receptors and facilitates acquisition of protective immunity J. Exp. Med., January 23, 2006; 203(1): 177 - 188. [Abstract] [Full Text] [PDF]

				Z. L. Chang, D. Netski, P. Thorkildson, and T. R. Kozel Binding and Internalization of Glucuronoxylomannan, the Major Capsular Polysaccharide of Cryptococcus neoformans, by Murine Peritoneal Macrophages Infect. Immun., January 1, 2006; 74(1): 144 - 151. [Abstract] [Full Text] [PDF]

				R. A. Larsen, P. G. Pappas, J. Perfect, J. A. Aberg, A. Casadevall, G. A. Cloud, R. James, S. Filler, and W. E. Dismukes Phase I Evaluation of the Safety and Pharmacokinetics of Murine-Derived Anticryptococcal Antibody 18B7 in Subjects with Treated Cryptococcal Meningitis Antimicrob. Agents Chemother., March 1, 2005; 49(3): 952 - 958. [Abstract] [Full Text] [PDF]

				A. Casadevall and L.-a. Pirofski New Concepts in Antibody-Mediated Immunity Infect. Immun., November 1, 2004; 72(11): 6191 - 6196. [Full Text] [PDF]

				T. P. Plackett, E. D. Boehmer, D. E. Faunce, and E. J. Kovacs Aging and innate immune cells J. Leukoc. Biol., August 1, 2004; 76(2): 291 - 299. [Abstract] [Full Text] [PDF]

				M. Colmenares, S. L. Constant, P. E. Kima, and D. McMahon-Pratt Leishmania pifanoi Pathogenesis: Selective Lack of a Local Cutaneous Response in the Absence of Circulating Antibody Infect. Immun., December 1, 2002; 70(12): 6597 - 6605. [Abstract] [Full Text] [PDF]

				Q. Chang, Z. Zhong, A. Lees, M. Pekna, and L. Pirofski Structure-Function Relationships for Human Antibodies to Pneumococcal Capsular Polysaccharide from Transgenic Mice with Human Immunoglobulin Loci Infect. Immun., September 1, 2002; 70(9): 4977 - 4986. [Abstract] [Full Text] [PDF]

				K. Westin Kwon, N. Lendvai, S. Morrison, K. R. Trinh, and A. Casadevall Biological Activity of a Mouse-Human Chimeric Immunoglobulin G2 Antibody to Cryptococcus neoformans Polysaccharide Clin. Vaccine Immunol., January 1, 2002; 9(1): 201 - 204. [Abstract] [Full Text] [PDF]